Table 1.
Correlation between IMPDH2 expression and clinical and pathological characters in NPC patients.
| Variable | All cases N = 226 (%) | IMPDH2 protein | P value | ||
|---|---|---|---|---|---|
| Low expression N = 103 (%) | High expression N = 123 (%) | χ2 | |||
| Age(years) | 0.054 | 0.817 | |||
| ≤44 | 116 (51.3) | 52 (44.8) | 64 (55.2) | ||
| >44 | 110 (48.7) | 51 (46.4) | 59 (53.6) | ||
| Mean ± SD(44.4 ± 11.4) | |||||
| Gender | 1.097 | 0.295 | |||
| Female | 52 (23.0) | 27 (51.9) | 25 (48.1) | ||
| Male | 174 (77.0) | 76 (43.7) | 98 (56.3) | ||
| VCA-IgA | 1.713 | 0.191 | |||
| <1:80 | 32 (14.2) | 18 (56.3) | 14 (43.7) | ||
| ≥1:80 | 194 (85.8) | 85 (43.8) | 109 (56.2) | ||
| EA-IgA | 0.705 | 0.401 | |||
| <1:10 | 64 (28.3) | 32 (50.0) | 32 (50.0) | ||
| ≥1:10 | 162 (71.7) | 71 (43.8) | 91 (56.2) | ||
| T classification | 5.188 | 0.023* | |||
| T1-2 | 85 (37.6) | 47 (55.3) | 38 (44.7) | ||
| T3-4 | 141 (62.4) | 56 (39.7) | 85 (60.3) | ||
| N classification | 0.362 | 0.547 | |||
| N0 | 55 (24.3) | 27 (49.1) | 28 (50.9) | ||
| N1-3 | 171 (75.7) | 76 (44.4) | 95 (55.6) | ||
| TNM stage | 5.390 | 0.020* | |||
| I-II | 64 (28.3) | 37 (57.8) | 27 (42.2) | ||
| III-IV | 162 (71.7) | 66 (40.7) | 96 (59.3) | ||
| WHO type | <0.001 | 0.990 | |||
| I + II | 22 (9.7) | 10 (45.5) | 12 (54.5) | ||
| III | 204 (90.3) | 93 (45.6) | 111 (54.4) | ||
| Distant metastasis | 10.561 | 0.001* | |||
| Yes | 61 (27.0) | 17 (27.9) | 44 (72.1) | ||
| No | 165 (73.0) | 86 (52.1) | 79 (47.9) | ||
| Death | 9.919 | 0.002* | |||
| Yes | 50 (22.1) | 13 (26.0) | 37 (74.0) | ||
| No | 176 (77.9) | 90 (51.1) | 86 (48.9) | ||
VCA-IgA: viral capsid antigen immunoglobulin A; EA-IgA: early antigen immunoglobulin A; WHO: World Health Organization; P-values*were calculated using the chi-square test or Fisher’s exact test.